tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

Genmab launches partnership with OpenAI for ‘AI Everywhere’
The FlyGenmab launches partnership with OpenAI for ‘AI Everywhere’
17h ago
AAPL
GMAB
Genmab announces new data from Phase 1/2 study of Rina-S
PremiumThe Fly
Genmab announces new data from Phase 1/2 study of Rina-S
5d ago
GMAB
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
PremiumPress Releases
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
5d ago
GMAB
Capital Increase in Genmab as a Result of Employee Warrant Exercise
PremiumPress Releases
Capital Increase in Genmab as a Result of Employee Warrant Exercise
9d ago
GMAB
Genmab price target lowered to $50 from $53 at Truist
PremiumThe Fly
Genmab price target lowered to $50 from $53 at Truist
11d ago
GMAB
Genmab resumed with an Equal Weight at Morgan Stanley
PremiumThe FlyGenmab resumed with an Equal Weight at Morgan Stanley
16d ago
GMAB
Hookipa Pharma appoints O’Neill as non-executive chair of board
Premium
The Fly
Hookipa Pharma appoints O’Neill as non-executive chair of board
21d ago
GMAB
HOOK
Genmab price target lowered to DKK 2,500 from DKK 2,750 at Deutsche Bank
Premium
The Fly
Genmab price target lowered to DKK 2,500 from DKK 2,750 at Deutsche Bank
21d ago
GMAB
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
PremiumPress Releases
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
25d ago
GMAB
Genmab downgraded to Neutral from Overweight at JPMorgan
PremiumThe Fly
Genmab downgraded to Neutral from Overweight at JPMorgan
1M ago
GMAB
AbbVie announces European Commission approval for Tepkinly for second indication
PremiumThe Fly
AbbVie announces European Commission approval for Tepkinly for second indication
1M ago
ABBV
GMAB
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
PremiumPress Releases
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
1M ago
GMAB
Genmab receives second European Commission approval for Tepkinly
PremiumThe FlyGenmab receives second European Commission approval for Tepkinly
1M ago
GMAB
Genmab Announces Changes to its Executive Committee
Premium
Press Releases
Genmab Announces Changes to its Executive Committee
1M ago
GMAB
Genmab COO Anthony Mancini to depart, Rayne Waller named CTO
Premium
The Fly
Genmab COO Anthony Mancini to depart, Rayne Waller named CTO
1M ago
GMAB
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
PremiumPress Releases
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
1M ago
GMAB
Capital Increase in Genmab as a Result of Employee Warrant Exercise
PremiumPress Releases
Capital Increase in Genmab as a Result of Employee Warrant Exercise
1M ago
GMAB
Genmab reports 1H revenue increased 36% vs. last year
PremiumThe Fly
Genmab reports 1H revenue increased 36% vs. last year
1M ago
GMAB
Genmab Updates 2024 Financial Guidance
PremiumPress Releases
Genmab Updates 2024 Financial Guidance
1M ago
GMAB
Genmab Announces Financial Results for the First Half of 2024
PremiumPress ReleasesGenmab Announces Financial Results for the First Half of 2024
1M ago
GMAB
Genmab raises FY24 guidance for revenue, operating profit excluding charges
Premium
The Fly
Genmab raises FY24 guidance for revenue, operating profit excluding charges
1M ago
GMAB
Genmab to assume full control of development, commercialization of acasunlimab
Premium
The Fly
Genmab to assume full control of development, commercialization of acasunlimab
2M ago
BNTX
GMAB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >